Squamous cell carcinoma antigen in patients with cancer of the larynx

Lachowicz, M; Hassmann-Poznanska, E.; Kozłowski, Mirosław; Rzewnicki, Ireneusz

doi:10.1046/j.1365-2273.1999.00239.x

Cited by 9 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the pro-invasive ability of SCC-Ag has been supported by clinical studies demonstrating positive relationships between serum SCC-Ag levels and tumor progression, lymph node metastasis, and tumor stage. [4], [13], [19], [24], [25], [26] In our study, we demonstrated that the SCC-Ag was significantly lower after treatment in OSCC (Fig. S1A).…”

Section: Discussionsupporting

confidence: 54%

Using SCC Antigen and CRP Levels as Prognostic Biomarkers in Recurrent Oral Cavity Squamous Cell Carcinoma

et al. 2014

View full text Add to dashboard Cite

Squamous cell carcinoma antigen (SCC-Ag) and C-reactive protein (CRP) levels have been successfully used to stratify risk groups in primary oral squamous cell carcinoma (OSCC) patients; however, related biomarkers have rarely been investigated in recurrent OSCC. The purpose of the present study was to analyze the relationships of SCC-Ag and CRP levels at the time of recurrence with clinical factors and prognosis. We retrospectively recruited patients with recurrence in a cohort of 534 OSCC patients between March 2001 and July 2013. One hundred patients had recurrence. The serum SCC-Ag and CRP levels were measured at the time of cancer diagnosis, 3 to 6 months after treatment with clinical disease-free, and at the time of recurrence. The SCC-Ag levels were significantly lowered after treatment (paired t-test: p = 0.001) and re-elevated at the time of recurrence (paired t-test: p = 0.027). An SCC-Ag level ≥2.0 ng/ml and a CRP level ≥5.0 mg/L at the time of recurrence were significantly associated with recurrent tumor status (P<0.001), recurrent nodal metastasis (χ2 trend test: P = 0.020), distant metastasis (P<0.001), and overall survival (P<0.001). Moreover, the influence of both elevated SCC-Ag and CRP levels on overall survival (P<0.001, H.R. [95% CI]: 5.406 [2.210–13.222]) still existed after adjusting for the recurrent tumor stage and patient age. The present study demonstrates that concurrent high levels of both SCC-Ag and CRP at the diagnosis of recurrence acts as a predictor of recurrent tumor status, recurrent advanced tumor stage, distant metastasis, and survival after the diagnosis of recurrence. This study expands the applicability of these two markers in the risk stratification in recurrent OSCC.

show abstract

Section: Discussionsupporting

confidence: 54%

Using SCC Antigen and CRP Levels as Prognostic Biomarkers in Recurrent Oral Cavity Squamous Cell Carcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…24,25 One study reported that pretreatment levels of squamous cell antigen were positively associated with disease recurrence in 70 patients with laryngeal cancer, indicating a potential role as a prognostic marker, although whether this marker added to or simply reflected known prognostic factors was not evaluated. 26 We found that sVEGFR1 was neither raised in patients with HNSCC nor related to clinicopathologic or outcome measures. It therefore does not have a role as a circulating tumor or prognostic marker.…”

Section: Discussionmentioning

confidence: 97%

Soluble Tie‐2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma

et al. 2002

View full text Add to dashboard Cite

show abstract

“…This protein was detected in our ADC and SCC pools with spectral counts of 14 and 10, respectively (supplemental Table S5). Squamous cell carcinoma antigen (SCC) is also a well-known tumor marker frequently observed in lung and laryngeal cancer patients' sera (38,39). We observed this molecule with a spectral count of 13 in the SCC pool and three in the ADC pool.…”

Section: Nsclc Shotgun Proteomic Analysis Detection Coveragementioning

confidence: 89%

In-depth Proteomic Analysis of Nonsmall Cell Lung Cancer to Discover Molecular Targets and Candidate Biomarkers

Kikuchi

Hassanein

Amann

et al. 2012

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Advances in proteomic analysis of human samples are driving critical aspects of biomarker discovery and the identification of molecular pathways involved in disease etiology. Toward that end, in this report we are the first to use a standardized shotgun proteomic analysis method for in-depth tissue protein profiling of the two major subtypes of nonsmall cell lung cancer and normal lung tissues. We identified 3621 proteins from the analysis of pooled human samples of squamous cell carcinoma, adenocarcinoma, and control specimens. In addition to proteins previously shown to be implicated in lung cancer, we have identified new pathways and multiple new differentially expressed proteins of potential interest as therapeutic targets or diagnostic biomarkers, including some that were not identified by transcriptome profiling. Up-regulation of these proteins was confirmed by multiple reaction monitoring mass spectrometry. A subset of these proteins was found to be detectable and differentially present in the peripheral blood of cases and matched controls. Label-free shotgun proteomic analysis allows definition of lung tumor proteomes, identification of biomarker candidates, and potential targets for therapy. Molecular & Cellular Proteomics 11: 10.1074/mcp.M111.015370, 916 -932, 2012.Lung cancer is one of the deadliest cancers, with ϳ200,000 newly diagnosed individuals and 160,000 deaths every year in the United States (1). Despite the most advanced treatments that modern medicine has to offer, the five-year survival rate remains less than 15%. Although a small subset of tumors have been found to be driven by single mutated oncogenes for which active, but still noncurative, therapies are available, the vast majority of patients have complex multifactorial disease with few effective therapeutic options. New early detection strategies and molecular therapeutic targets are urgently needed to improve patient survival.Genomic analysis has enabled us to measure the sequence, copy number, and expression changes of thousands of genes simultaneously, which can be used to discover transcripts specifically altered or expressed in tumor tissues (2-4). Although genomic studies have given important new insights into the mechanisms of carcinogenesis, therapeutic targets, and most practical biomarkers are their protein products, and the correlation between transcript sequence or level and protein function remains complex and poorly understood. Protein expression, in part, depends on transcript levels, but it is clear that significant translational and post-translational regulation of protein levels and function occurs, adding another level of complexity in the regulation of activity, especially in tumor cells (5, 6). It would be ideal to have a comprehensive understanding of the novel changes in protein expression levels and the modifications of proteins in cancer cells, but the technology to directly study proteomes has lagged behind that to assess genomes and transcriptomes. We and others have used matrix-assisted laser desorption and...

show abstract

Squamous cell carcinoma antigen in patients with cancer of the larynx

Cited by 9 publications

References 24 publications

Using SCC Antigen and CRP Levels as Prognostic Biomarkers in Recurrent Oral Cavity Squamous Cell Carcinoma

Using SCC Antigen and CRP Levels as Prognostic Biomarkers in Recurrent Oral Cavity Squamous Cell Carcinoma

Soluble Tie‐2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma

In-depth Proteomic Analysis of Nonsmall Cell Lung Cancer to Discover Molecular Targets and Candidate Biomarkers

Contact Info

Product

Resources

About